CTC
BMY.RT

Central Trust Company’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Central Trust Company’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,483
Closed -$9K – 1164
2020
Q4 		$9K Sell
12,483
-41,155
-77% -$87.7K ﹤0.01% 909
2020
Q3 		$120K Hold
53,638
– – 0.01% 522
2020
Q2 		$192K Sell
53,638
-13,631
-20% -$49.2K 0.01% 445
2020
Q1 		$256K Sell
67,269
-618
-0.9% -$2.04K 0.02% 386
2019
Q4 		$205K Buy
+67,887
New +$177K 0.01% 454

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Central Trust Company's BMY.RT Position: Q1 2021 in Review

Central Trust Company sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 12,483 shares — an estimated $9K sold.

Central Trust Company first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $256K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Central Trust Company reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Central Trust Company sold 12,483 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $9K.
  • Central Trust Company first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Central Trust Company's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $256K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Central Trust Company's 13F filing for Q1 2021, filed 23 Apr 2021.